Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Neuroendocrine 12Adrenocortical Carcinoma 9Neuroendocrine Tumors 5Small Cell Lung Carcinoma 4Thyroid Carcinoma, Anaplastic 3Peritoneal Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Somatostatinoma 2Sarcoma 2Neoplasms 2Head and Neck Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Small Cell 2Wilms Tumor 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rhabdomyosarcoma 1Retroperitoneal Neoplasms 1Pheochromocytoma 1Ovarian Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroendocrine Neoplasms 1Neuroblastoma 1Mesothelioma, Malignant 1Medulloblastoma 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Neoplasms × Cisplatin × Endocrine × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡